Axa’s PDL BioPharma, Inc. PDLI Stock Holding History

Axa’s Portfolio PDLI Stock Details PDLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-318,608	Closed	-$928K	–	1394
2020 Q3	$928K	Hold	318,608	–	–	﹤0.01%	953
2020 Q2	$927K	Sell	318,608 -40,500	-11%	-$128K	﹤0.01%	968
2020 Q1	$1.01M	Buy	359,108 +35,908	+11%	+$116K	0.01%	852
2019 Q4	$1.05M	Hold	323,200	–	–	﹤0.01%	882
2019 Q3	$698K	Buy	323,200 +250,000	+342%	+$668K	﹤0.01%	1045
2019 Q2	$230K	Buy	+73,200	New	+$237K	﹤0.01%	1209
2019 Q1	–	Sell	-20,700	Closed	-$60K	–	1444
2018 Q4	$60K	Hold	20,700	–	–	﹤0.01%	1286
2018 Q3	$54K	Sell	20,700 -130,200	-86%	-$320K	﹤0.01%	1323
2018 Q2	$353K	Sell	150,900 -135,600	-47%	-$379K	﹤0.01%	1199
2018 Q1	$842K	Sell	286,500 -52,300	-15%	-$143K	﹤0.01%	1043
2017 Q4	$928K	Buy	338,800 +318,100	+1,537%	+$977K	﹤0.01%	1023
2017 Q3	$70K	Buy	+20,700	New	+$57.6K	﹤0.01%	1303
2017 Q1	–	Sell	-131,000	Closed	-$278K	–	1365
2016 Q4	$278K	Sell	131,000 -157,800	-55%	-$440K	﹤0.01%	1159
2016 Q3	$967K	Sell	288,800 -17,600	-6%	-$55.9K	﹤0.01%	908
2016 Q2	$962K	Sell	306,400 -58,300	-16%	-$194K	﹤0.01%	886
2016 Q1	$1.21M	Sell	364,700 -190,000	-34%	-$592K	0.01%	837
2015 Q4	$1.96M	Sell	554,700 -15,600	-3%	-$65.3K	0.01%	771
2015 Q3	$2.87M	Buy	570,300 +26,400	+5%	+$151K	0.01%	703
2015 Q2	$3.5M	Sell	543,900 -24,300	-4%	-$163K	0.01%	660
2015 Q1	$4M	Buy	568,200 +43,500	+8%	+$315K	0.02%	653
2014 Q4	$4.04M	Sell	524,700 -378,300	-42%	-$2.99M	0.02%	612
2014 Q3	$6.75M	Buy	903,000 +262,500	+41%	+$2.44M	0.03%	462
2014 Q2	$6.2M	Buy	640,500 +12,500	+2%	+$111K	0.03%	497
2014 Q1	$5.22M	Buy	628,000 +275,300	+78%	+$2.36M	0.02%	511
2013 Q4	$2.98M	Buy	352,700 +80,900	+30%	+$682K	0.01%	677
2013 Q3	$2.17M	Buy	271,800 +24,500	+10%	+$197K	0.01%	722
2013 Q2	$1.91M	Buy	+247,300	New	+$1.93M	0.01%	717

Other funds holding PDLI

SPC

Silver Point Capital Greenwich, Connecticut $1.1B AUM 20.71% 1-Year Est. Return

PWAM

Park West Asset Management San Francisco, California $1.47B AUM 86.42% 1-Year Est. Return

GCIA

Gabelli & Co Investment Advisers Rye, New York $688M AUM 63.39% 1-Year Est. Return

JBF Capital Aspen, Colorado $764M AUM 24.26% 1-Year Est. Return

Gabelli Funds Rye, New York $15.7B AUM 36.4% 1-Year Est. Return

CCM

Context Capital Management Lajolla, California $5.15B AUM 1.28% 1-Year Est. Return

Winton Group London, United Kingdom $3.09B AUM 40.4% 1-Year Est. Return

California Public Employees Retirement System Sacramento, California $177B AUM 39.86% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return

Hancock Whitney Gulfport, Mississippi $6B AUM 34.57% 1-Year Est. Return

Axa's PDLI Position: Q4 2020 in Review

Axa sold out of PDL BioPharma, Inc. (PDLI) in Q4 2020, closing a stake of 318,608 shares — an estimated $928K sold.

Axa first reported a position in PDLI in Q2 2013 and held it in 27 quarters. The position peaked at $6.75M in Q3 2014. 33 funds tracked by Wall St. Rank hold PDLI as of Q4 2020.

Axa reported no remaining PDL BioPharma, Inc. position as of Q4 2020 after selling out during the quarter.
Axa sold 318,608 PDL BioPharma, Inc. shares in Q4 2020, an estimated $928K.
Axa first reported a position in PDL BioPharma, Inc. in Q2 2013 and held it in 27 quarters.
Axa's PDL BioPharma, Inc. position peaked at $6.75M in Q3 2014.
33 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q4 2020.

Based on Axa's 13F filing for Q4 2020, filed 12 Feb 2021.